The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 01, 2013
Filed:
May. 22, 2012
Nicole Blaquiere, South San Francisco, CA (US);
Steven DO, South San Francisco, CA (US);
Danette Dudley, South San Francisco, CA (US);
Adrian Folkes, Basel, CH;
Robert Heald, Harlow, GB;
Timothy Heffron, South San Francisco, CA (US);
Mark Jones, Harlow, GB;
Aleksandr Kolesnikov, South San Francisco, CA (US);
Chudi Ndubaku, South San Francisco, CA (US);
Alan G. Olivero, South San Francisco, CA (US);
Stephen Price, Harlow, GB;
Steven Staben, South San Francisco, CA (US);
Lan Wang, South San Francisco, CA (US);
Nicole Blaquiere, South San Francisco, CA (US);
Steven Do, South San Francisco, CA (US);
Danette Dudley, South San Francisco, CA (US);
Adrian Folkes, Basel, CH;
Robert Heald, Harlow, GB;
Timothy Heffron, South San Francisco, CA (US);
Mark Jones, Harlow, GB;
Aleksandr Kolesnikov, South San Francisco, CA (US);
Chudi Ndubaku, South San Francisco, CA (US);
Alan G. Olivero, South San Francisco, CA (US);
Stephen Price, Harlow, GB;
Steven Staben, South San Francisco, CA (US);
Lan Wang, South San Francisco, CA (US);
Genentech, Inc., South San Francisco, CA (US);
Abstract
Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.